Annabel Kartal-Allen is a reporter for Clinical Trials Arena, Pharmaceutical Technology and Medical Device Network based in London, UK. Annabel holds interests in oncology, neurology and metabolic diseases. She has previous experience reporting for both the pharmaceutical and nutraceutical industries, and holds a BSc in Biology from the University of Sussex. Contact Annabel
Bayer’s radioligand therapy (RLT), Xofigo (radium-223 dichloride), has demonstrated its first-line, combinatory treatment potential in metastatic castration resistant prostate cancer…
Eli Lilly’s Omvoh (mirikizumab) has demonstrated its capacity to keep patients free from corticosteroids and promote long-term clinical remission in…
Compass Pathways’ stock is up 31% after the company posted another positive Phase III readout for its investigational psychedelic, COMP360,…
Helus Pharma’s psychedelic compound, SPL026, has demonstrated its potential to treat major depressive disorder (MDD) in a mid-stage study. During…
Roche is heading to regulators after its blockbuster kidney disease candidate, Gazyva (obinutuzumab), met its primary endpoint during a Phase…
A report from the Association of the British Pharmaceutical Industry (ABPI) has suggested that a disharmony between academia and industry…
BridgeBio is heading to regulators after its achondroplasia therapy, infigratinib, met its primary and secondary endpoints in a pivotal study.…
Upstream Bio’s stock value took a 47% downturn following the debut of topline results from a Phase II trial on…
Nektar Therapeutics stock has rallied 51% after its lead asset, rezpeg (rezpegaldesleukin), demonstrated potential across monthly and quarterly maintenance dosing…
Autoimmune specialist Zenas BioPharma has posted a win for its lead candidate, obexelimab, from a mid-stage study in relapsing multiple…
